Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease primarily affecting motor neurons. Recently,1 Miller et al. presented phase 3 data for the RNase-H-recruiting antisense oligonucleotide (ASO) targeting superoxide dismutase 1 (SOD1) in ALS, which represents a step forward in the deployment of ASO therapeutics against CNS targets.

Original publication

DOI

10.1016/j.medj.2022.10.004

Type

Journal article

Journal

Med (N Y)

Publication Date

11/11/2022

Volume

3

Pages

733 - 734

Keywords

Humans, Amyotrophic Lateral Sclerosis, Ribonuclease H, Neurodegenerative Diseases, Superoxide Dismutase-1, Superoxide Dismutase, Oligonucleotides, Antisense